Resmed SEC Filings

ResMed insider notice to sell 3,000 common shares via Fidelity on 09/02/2025. The filing reports an aggregate market value of $812,310 for the proposed sale and states the company has 146,414,839 shares outstanding. The shares to be sold were acquired through an options grant (11/14/2018) covering 2,000 shares and restricted stock vesting on 11/11/2022 (204 shares) and 11/18/2022 (796 shares). The filer also disclosed three prior sales over the past three months by Brett Sandercock totaling 7,883 shares for gross proceeds of $2,087,372.17. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information.

Justin Leong, Chief Product Officer of ResMed Inc. (RMD), reported that 5,462 shares of company stock were acquired on 08/15/2025 upon the vesting of performance-based restricted stock units. These units were originally granted on 11/20/2024 and were certified as earned by the compensation committee when the performance metrics were met.

Following the transaction, Mr. Leong beneficially owns 27,180 shares. The reported acquisition shows a transaction code of A(1) with a reported price of $0, consistent with earned compensation rather than a market purchase.

Brett Sandercock, Chief Financial Officer of ResMed Inc. (RMD), reported that 5,462 shares of ResMed common stock were issued to him on 08/15/2025 as the result of performance-based restricted stock units (RSUs) granted on 11/20/2024. The filing shows the shares were earned when the company's compensation committee certified that the performance metrics were met; the RSUs have a vesting schedule of one-third each anniversary of the grant.

Following this issuance, Mr. Sandercock beneficially owns 88,745 shares. The reported transaction lists a price of $0, reflecting the settlement of vested RSUs rather than an open-market purchase, and the Form 4 is signed and dated 08/19/2025.

ResMed Inc. Chief Executive Officer Michael J. Farrell reported the vesting and receipt of performance-based restricted stock units. On 08/15/2025, 12,289 shares of ResMed common stock were acquired at a $0 price because they were earned under a performance-based restricted stock unit award granted 11/20/2024 after the compensation committee certified that performance metrics were met. After the transaction, Farrell beneficially owned 467,792 shares directly and held an indirect interest in 2,090 shares through the Lisette and Michael Farrell Family Trust. The award vests one-third each year on the grant anniversary.

ResMed Inc. (RMD) director John Hernandez exercised stock options and sold the resulting shares on 08/18/2025. He executed option exercises totaling 2,575 shares at an exercise price of $148.90 per share and concurrently sold 2,575 shares at a weighted average sale price of $287.1026. Following these transactions his beneficial ownership decreased from 6,620 shares to 4,045. The filing notes options became exercisable on 11/11/2024 (with vesting rules) and that the sale price range was $286.90–$287.24.

Insider acquisition of ResMed common stock via vested performance awards. Michael J. Rider, Global General Counsel and Secretary of ResMed Inc. (RMD), reported that 2,941 shares of ResMed common stock were acquired on 08/15/2025 at a $0 price as the result of performance-based restricted stock units granted on 11/20/2024 that vested when the compensation committee certified performance metrics were met. After the transaction, Rider beneficially owns 11,427 shares. The filing indicates the award vests in one-third increments annually on the grant anniversary; no cash purchase occurred. This Form 4 was signed on 08/19/2025.

ResMed (RMD) Form 144 notice: An insider intends to sell 2,575 shares of ResMed common stock on the NYSE through Fidelity Brokerage Services. The filing lists an aggregate market value of $739,289.14 and shows 146,414,839 shares outstanding. The securities were reported as acquired in connection with an option granted on 11/16/2023 and listed as acquired and scheduled for sale on 08/18/2025. The transaction is shown as a cash sale through the named broker. The filer states they are not aware of undisclosed material adverse information about the issuer.